Background: Interferon response triggered by acute HIV infection modulates the expression of genes in both infected and non-infected cells to control viral replication and virus spread. To date, a number of genes have been identified as host antiviral factors that interfere with various steps of the HIV replication cycle. Members of the interferon-induced transmembrane proteins (IFITMs) are induced in human macrophages and CD4+ T cells upon upon exposure to interferons. While IFITMs have been shown to inhibit entry of HIV-1, the effects of IFITMs on other stages of the viral replication cycle are not known. Thus, we investigated the effects of IFITMs expression on the post-entry steps of the HIV replication cycle and how post-translational modification of IFITMs modulates these effects.
Methods: In transfection assays, wild-type or accessory gene-deleted HIV proviral DNA and expression vectors for IFITM1-3 were co-transfected into adherent HEK293T cells. In infection assays, HIV-1 viruses were made from transfected 293T cells and subsequently used to infect SupT1 cells that express human IFITMs upon exposure to doxycycline. Virus released from transfected or infected cells was quantified by p24 ELISA. Expression of viral proteins, IFITMs and other antiviral proteins were evaluated by immunoblotting or intracellular staining and flow cytometry. Quantitative PCR was used to measure the amount of total, multiply-spliced and singly-spliced viral RNA. Immunofluorescence and confocal microscopy were used to visualize IFITMs and viral components in cells.
Results: We show that expression of human IFITMs reduces the quantity of released HIV-1 viral particles produced in cells compared to vector controls. In the absence of the HIV accessory proteins Nef and Vpu, IFITM-mediated antagonism of HIV is more potent (20-30 fold). The reduction of viral output is caused by a decrease in synthesis of viral proteins independent of transcriptional control. While mutation of cysteine residues in IFITM1-2 that perturbs their palmitoylation and concomitant plasma membrane retention led to a reduction in all classes of viral RNA transcripts. This results in highly reduced HIV particle output by 10 to 100-fold compared to the wild-type IFITM1.
Conclusions: Our studies identify a novel role for IFITMs in controlling HIV replication at the post-transcriptional level and show that it is possible to engineer highly active anti-HIV IFITM variants by modulation of their palmitoylation status.